Session 2: Molecular Diagnostics

Allegra, C. and D. Sargent (2003). “Molecular Diagnostics: Assays, Tissues, Progress, and Pitfalls.” J Clin Oncol 21: 395—6.

Bertucci, F. , P. Viens , P. Hingamp , et al. (2003). “Breast Cancer Revisited Using DNA Array-Based Gene Expression Profiling.” Int J Cancer 103: 565—71.

Bertucci, F. , P. Viens , R. Tagett , et al. (2003). “DNA Arrays in Clinical Oncology: Promises and Challenges.” Lab Invest 83: 305—16.

Bustin, S.A. and S. Dorudi (2002). “The Value of Microarray Techniques for Quantitative Gene Profiling in Molecular Diagnostics.” Trends Mol Med 8: 269—72.

Ciro, M. , A.P. Bracken , and K. Helin (2003). “Profiling Cancer.” Curr Opin Cell Biol 15: 213—20.

Farkas, D.H. (2002). “Molecular Diagnostics: the Best is Yet to Come.” Trends Mol Med 8: 245.

Fortina, P. , S. Surrey , and L.J. Kricka (2002). “Molecular Diagnostics: Hurdles for Clinical Implementation.” Trends Mol Med 8: 264—6.

Goessl, C. (2003). “Noninvasive Molecular Detection of Cancer—The Bench and the Bedside.” Curr Med Chem 10: 691—706.

Hampton, G.M. and H.F. Frierson (2003). “Classifying Human Cancer by Analysis of Gene Expression.” Trends Mol Med 9: 5—10.

Iacopetta, B. (2003). “Aberrant DNA Methylation: Have We Entered the Era of More Than One Type of Colorectal Cancer?” Am J Pathol 162: 1043—5.

Johnson, J.A. and W.E. Evans (2002). “Molecular Diagnostics as a Predictive Tool: Genetics of Drug Efficacy and Toxicity.” Trends Mol Med 8: 300—5.

Ladanyi, M. , W.C. Chan , T.J. Triche , and W.L. Gerald (2001). “Expression Profiling of Human Tumors: The End of Surgical Pathology?” J Mol Diagn 3: 92—7.

Lakhani, S.R. and A. Ashworth (2001). “Microarray and Histopathological Analysis of Tumours: The Future and the Past?” Nature Rev Cancer 2: 151—7.

Liefers, G.J. and R.A. Tollenaar (2002). “Cancer Genetics and Their Application to Individualised Medicine.” Eur J Cancer 38: 872—9.

Negm, R.S. , M. Verma , and S. Srivastava (2002). “The Promise of Biomarkers in Cancer Screening and Detection.” Trends Mol Med 8: 288—93.

Petricoin, E.F. 3rd , J.L. Hackett , L.J. Lesko , et al. (2002). “Medical Applications of Microarray Technologies: A Regulatory Science Perspective .” Nat Genet 32 (Suppl): 474—9.

Ramaswamy, S. and T.R. Golub (2002). “DNA Microarrays in Clinical Oncology.” J Clin Oncol 20: 1932—41.

Ramaswamy, S. and C.M. Perou (2003). “DNA Microarrays in Breast Cancer: The Promise of Personalised Medicine.” Lancet 361: 1576—7.

Ransohoff, D.F. (2003). “Developing Molecular Biomarkers for Cancer .” Sciencept 299: 1679—80.

Schatzkin, A. and M. Gail (2002). “The Promise and Peril of Surrogate End Points in Cancer Research.” Nat Rev Cancer 2: 19—27.

Shi, H. , S. Maier , I. Nimmrich , et al. (2003). “Oligonucleotide-Based Microarray for DNA Methylation Analysis: Principles and Applications.” J Cell Biochem 88: 138—43.

Sidransky, D. (2002). “Emerging Molecular Markers of Cancer,” Nature Rev Cancer 3: 210—9.

Srinivas, P.R. , S. Srivastava , S. Hanash , and G.L. Wright Jr (2001). “Proteomics in Early Detection of Cancer,” Clin Chem 10: 1901—11.

Steimer, W. and J.M. Potter (2002). “Pharmacogenetic Screening and Therapeutic Drugs.” Clin Chim Acta 1—2: 137—55.

Sturgeon, C. (2002). “Practice Guidelines for Tumor Marker Use in the Clinic.” Clin Chem 48: 1151—9.

Ubel, P.A. , C. Jepson , J. Baron , et al. (2003). “The Influence of Cost-Effectiveness Information on Physicians' Cancer Screening Recommendations.” Soc Sci Med 56: 1727—36.

van de Vijver, M.J. , Y.D. He , L.J. van't Veer , et al. (2002). “Gene-Expression Signature as a Predictor of Survival in Breast Cancer.” N Engl J Med 19: 1999—2009.

Verma, M. and S. Srivastava (2002). “Epigenetics in Cancer: Implications for Early Detection and Prevention.” Lancet Oncol 3: 755—63.